Vikas Lifecare Limited (VIKASLIFE) AI Stock Analysis

• Market Cap: ₹2.34B
• Dividend Yield: N/A
• Average Volume (3M): 850.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: 9.42%
• EPS Growth: -12220.00%
• Country: IN
• Employees: 36
• Sector: Healthcare
• Sector Strength: 45
• Industry: Chemicals - Specialty
• EPS (TTM): N/A
• Shares Outstanding: 1,857,668,600
• 10 Day Avg. Volume: 448,294
• 30 Day Avg. Volume: 850,962
• PEG Ratio: 0.26
• Price to Book (P/B): 0.87
• Price to Sales (P/S): 0.96
• P/FCF Ratio: -1.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: ₹1.50 ▼(-16.67% Downside)
• Action: Reiterated Date: 03/11/26
• Date: Action: Reiterated 03/11/26

The score is primarily held back by weak financial performance (profitability decline, negative margins, and poor cash generation) and bearish technical conditions (below major moving averages with negative MACD). Valuation also screens poorly due to losses reflected in a negative P/E, with no dividend data to provide support.

Positive Factors

Multi‑sector distribution network

Vikas Lifecare’s role as a supplier across multiple end-use sectors and its sourcing, logistics and distribution network creates a durable business model. Broad end-market exposure and distribution capabilities reduce single-sector cyclicality and support steady order flow and supplier relationships.

Positive revenue growth trend

Reported revenue growth of ~9.4% indicates the company is expanding sales volumes or market share. For a trading/distribution business, sustained top-line growth helps absorb fixed costs, improve purchasing leverage and can be a foundation for margin recovery if cost structure is managed.

Relatively strong equity base and balanced leverage

A strong equity ratio and only moderate leverage provide financial resilience. This capital cushion supports working capital needs, absorbs operating losses in the near term and preserves access to funding for inventory or supplier credit—key for a distributor's operational continuity.

Negative Factors

Negative profitability and weak margins

Net margins have deteriorated into negative territory and gross margins are low, indicating persistent margin pressure. For a distribution-focused trader, negative profitability undermines sustainability: it erodes working capital, weakens supplier negotiating power and jeopardizes long‑term viability unless margins recover.

Poor cash generation and negative free cash flow

Negative operating cash flow and declining free cash flow point to liquidity stress in a working‑capital intensive model. Persistent cash deficits force reliance on external financing, increase interest costs, constrain inventory financing and limit the company's ability to invest or stabilize operations over months.

Rising debt and negative ROE

Significant debt growth alongside negative ROE raises financial risk: higher leverage increases interest burden and refinancing exposure while negative returns indicate shareholder capital is being consumed. This combination reduces strategic flexibility and raises solvency concerns if trends persist.

Vikas Lifecare Limited Business Overview & Revenue Model

Company Description

Vikas Lifecare Limited engages in the trading of various chemicals compounds, polymers, PVC resins, plastic granules, and products related to plastic industry in India. It operates through Real Estate, Trading- Polymers, Trading-Cashew Nuts, and Manufacturing divisions. The company is also involved in the real estate business; and the manufacture of recycled material for automotive, packaging, sheathing, and textile industries. In addition, it manufactures and sells polymer compounds, which include PE, PVC, V blend SOE, and polypropylene compounds, as well as thermo plastic rubber; deals in FMCG, cashew nuts, aluminum foils, and processed food products. Vikas Lifecare Limited also exports its products. The company was formerly known as Vikas Multicorp Limited and changed its name to Vikas Lifecare Limited in April 2021. Vikas Lifecare Limited was incorporated in 1995 and is based in New Delhi, India.

How the Company Makes Money

Vikas Lifecare Limited primarily makes money by selling industrial materials—mainly polymers and chemical products—to business customers. Its core revenue model is trading/distribution: it sources products (from domestic and/or international manufacturers where applicable), maintains an inventory and logistics pipeline, and sells these materials to manufacturers and processors at a margin over its procurement and handling costs. Key revenue streams therefore come from (1) sales of polymer and polymer-compound/related materials and (2) sales of chemical products and allied industrial inputs. Earnings are influenced by sales volumes, product mix, spreads between purchase and selling prices, working-capital efficiency (inventory and receivables), and market pricing cycles for polymers/chemicals. Specific details on major customer contracts, named strategic partnerships, or segment-wise revenue breakdowns are null.

Vikas Lifecare Limited Financial Statement Overview

Summary

Income statement is weak (45) with declining profitability and negative net margins; cash flow is also strained (50) with poor operating cash flow and negative free cash flow trends. Balance sheet is comparatively steadier (60) with a strong equity base, but rising debt and negative ROE keep the overall financial profile below average.

Income Statement

Vikas Lifecare Limited has shown volatile revenue growth with a notable decline in profitability. The gross profit margin is low, indicating cost pressures, and the net profit margin has deteriorated into negative territory, reflecting operational challenges. The EBIT and EBITDA margins have also weakened, contributing to financial instability.

Balance Sheet

The balance sheet demonstrates a moderate debt-to-equity ratio, suggesting a balanced approach to leveraging, though the debt has increased significantly over the year. The return on equity is negative due to net losses, but the equity ratio remains strong, indicating solid capital structure despite profitability challenges.

Cash Flow

Cash flow analysis reveals negative free cash flow growth and poor operating cash flow, indicating liquidity challenges. The operating cash flow to net income ratio is negative, reflecting operational inefficiencies. The company needs to improve cash generation to support its operations.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	4.80B	4.80B	4.46B	4.76B	3.01B	749.95M
Gross Profit	86.62M	38.79M	262.04M	243.20M	101.59M	112.35M
EBITDA	-16.41M	43.56M	240.93M	-160.98M	427.24M	43.39M
Net Income	-112.78M	-106.14M	140.29M	-152.99M	286.99M	-35.02M
Balance Sheet
Total Assets	0.00	7.29B	5.55B	4.55B	3.21B	1.49B
Cash, Cash Equivalents and Short-Term Investments	57.31M	431.74M	159.36M	113.13M	77.05M	1.88M
Total Debt	0.00	767.00M	344.90M	304.07M	230.77M	417.57M
Total Liabilities	-5.33B	1.96B	762.67M	1.21B	1.21B	822.82M
Stockholders Equity	5.33B	5.32B	4.77B	3.31B	1.99B	666.70M
Cash Flow
Free Cash Flow	0.00	-2.36B	-577.20M	-1.28B	-281.03M	-91.52M
Operating Cash Flow	0.00	-2.24B	-417.48M	-1.10B	-148.84M	-76.82M
Investing Cash Flow	0.00	1.03B	-906.01M	-366.38M	-385.14M	119.21M
Financing Cash Flow	0.00	1.12B	1.37B	1.51B	590.87M	-42.69M

Vikas Lifecare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIKASLIFE, the sentiment is Negative. The current price of 1.8 is above the 20-day moving average (MA) of 1.45, above the 50-day MA of 1.62, and below the 200-day MA of 2.09, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 18.38 is Positive, neither overbought nor oversold. The STOCH value of 17.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIKASLIFE.

Vikas Lifecare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZIMLAB	63 Neutral	₹3.14B	19.99	―	―	-5.82%	-59.22%
MEDICAMEQ	55 Neutral	₹3.70B	56.53	―	0.26%	-9.16%	49.09%
LYKALABS	54 Neutral	₹1.90B	-338,564.26	―	―	4.04%	-35.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALBERTDAVD	51 Neutral	₹3.85B	6.87	―	0.66%	-13.51%	-122.00%
VIKASLIFE	48 Neutral	₹2.34B	-32.50	―	―	9.42%	-12220.00%
NECLIFE	46 Neutral	₹2.47B	7.63	―	―	-30.27%	-3470.06%